Quick Answer
Dermata Therapeutics, Inc. reported Net Income of -$7.56 million for fiscal year 2025.
Dermata Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$7.56M | +38.5% |
| 2024 | -$12.29M | -57.6% |
| 2023 | -$7.79M | +18.9% |
| 2022 | -$9.61M | -21.6% |
| 2021 | -$7.90M | -144.2% |
| 2020 | -$3.24M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.69M | +46.7% | +0.5% |
| June 30, 2025 | -$1.70M | +39.9% | +26.2% |
| March 31, 2025 | -$2.30M | +26.5% | +27.4% |
| September 30, 2024 | -$3.17M | -84.6% | -12.2% |
| June 30, 2024 | -$2.83M | -66.3% | +9.7% |
| March 31, 2024 | -$3.13M | -39.9% | -82.3% |
| September 30, 2023 | -$1.72M | +29.1% | -1.0% |
| June 30, 2023 | -$1.70M | +37.7% | +24.1% |
- Dermata Therapeutics, Inc. showed an increase of +38.5% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Dermata Therapeutics, Inc.’s net income has declined by 133.5% (from -$3.24 million to -$7.56 million).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: